Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of acinetobacter bacteremia

Yonsei Medical Journal

Volumn 47, Issue 1, 2006, Pages 63-69

  Choi, Jun Yong ^a   Kim, Chang Oh ^a   Park, Yoon Seon ^a   Yoon, Hee Jung ^a   Shin, So Youn ^a   Kim, Young Keun ^a   Kim, Myung Soo ^a   Kim, Yeon A ^a   Song, Young Goo ^a   Yong, Dongeun ^a   Lee, Kyungwon ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acinetobacter; Bacteremia; Cefoperazone sulbactam; Imipenem cilastatin

Indexed keywords

CILASTATIN PLUS IMIPENEM; SULPERAZON;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION CONTROL; KOREA; MALE; MORTALITY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFOPERAZONE; CILASTATIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PROTEASE INHIBITORS; SULBACTAM;

EID: 33644812542     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.1.63     Document Type: Review

References (26)

1. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:1268-74.
2. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802.
3. Bergogne-Berezin E, Towner KJ. Acinetobacter spp as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9: 148-65.
4. Cisneros JM, Reyes MJ, Pachon J, Becerri B, Caballero FJ, Garcia-Garmendia JL, et al. Bacteremia due to Acibetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026-32.
5. Lee K, Kim YA, Park YJ, Lee HS, Kim MY, Kim EC, et al. Increasing prevalence of vancomycin-resistant Enterococci, and cefoxitin-, imipenem- and fluoro-quinolone-resistant Gram-negative bacilli: a KONSAR study in 2002. Yonsei Med J 2004;45:598-608.
6. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8:144-53.
7. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425-30.
8. Farmer JJ III. Enterobacteriaceae: introduction and identification. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th ed. Washington DC: American Society for Microbiology; 1999. p.442-58.
9. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility testing-twelfth informational supplement. NCCLS document M100-S12. Wayne, Pa, National Committee for Clinical Laboratory Standards, 2002.
10. Garner JS, Jarvis. WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
11. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115: 529-35.
12. Cisneros JM, Rodriquez-Banño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002;8: 687-93.
13. Obana Y, Nishino T. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J Antimicrob Chemother 1990;26:677-82.
14. Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R, et al. In vitro antimicrobial production of betalactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferae by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993;37:138-41.
15. Rodriquez-Hernandez MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jimenez-Mejias ME, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001;47:479-82.
16. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142-8.
17. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-5l.
18. Lim VK, Cheong YM. In vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital. Malays J Pathol 1995;17:73-6.
19. Jones RN, Wilson HW, Thornsberry C, Barry AL. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbiol Infect Dis 1985;3:489-99.
20. Eliopoulos GM, Klimm K, Ferraro MJ, Moellering RCJ. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates. Eur J Clin Microbiol Infect Dis 1989;8:624-6.
21. Knapp CC, Sierra-Madero J, Washington JA. Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam. Diagn Microbiol Infect Dis 1989;13:45-9.
22. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acibetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trend in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001;32 Suppl 2:S104-13.
23. Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales; AC, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Diagn Microbiol Infect Dis 1999; 34:123-34.
24. Jones RN, Salazar JC, Pfaller MA, Doern GV. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. Diagn Microbiol. Infect Dis 1997;29:265-72.
25. Wood CA, Reboli AC. Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
26. Levin AS, Barone AA, Penco J, Santos MV, Marinho, IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.